The consensus price target hints at a 163.4% upside potential for Q32 Bio (QTTB). While empirical research shows that this ...
Q32 Bio's Bempikibart and ADX-097 are in Phase 2 trials, targeting autoimmune and inflammatory diseases, with significant potential to address unmet medical needs. The company's unique approach of ...
Q32 Bio (QTTB) closed the last trading session at $34.43, gaining 31.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...
Shares of Q32 Bio QTTB lost nearly 77% yesterday after it reported mixed results from two separate phase IIa studies evaluating its investigational drug bempikibart one in atopic dermatitis (AD or ...
On Wednesday, Q32 Bio Inc. (NASDAQ:QTTB) revealed topline results from the SIGNAL-AA Phase 2a signal finding trial evaluating bempikibart (ADX-914) for alopecia areata (AA). The company plans to ...
The latest price target for Q32 Bio (NASDAQ:QTTB) was reported by Wells Fargo on March 12, 2025. The analyst firm set a price target for $15.00 expecting QTTB to rise to within 12 months (a possible ...
On March 27, 2026, Q32 Bio Inc. entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., enabling at-the-market sales of its common stock under a prospectus supplement ...
Q32 Bio (QTTB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results